Summary
Amid ongoing reconciliation deliberations, the Wynne Health Group presents a side-by-side of the most pertinent drug pricing proposal provisions currently under consideration for inclusion in the final reconciliation package.
The chart presents provisions from the following:
- The Energy & Commerce and Ways & Means reconciliation recommendations;
- The House Moderate Democrats Reduced Costs and Continued Cures Act;
- The 2020 Senate Finance Prescription Drug Pricing Reduction Act (PDPRA);
- The Menendez-Cassidy Seniors Prescription Drug Relief Act; and
- The Crapo Lower Costs, More Cures Act.
The side-by-side compares provisions related to drug price negotiations, Part D redesign, inflation rebates, Part B reforms, and competition. We note that, while this chart does not include Senate reconciliation recommendations, as they have not been released yet, Senate Finance Chairman Sen. Ron Wyden (D-OR) is likely to feature provisions similar to those in current Senate proposals, with the possible addition of drug price negotiations that utilize a domestic reference price for instances in which negotiations fail.